A phase 3, randomized, double-blind, placebo-controlled, multicenter study to evaluate the efficacy and safety of vosoritide in children with hypochondroplasia: CANOPY HCH-3 study design Authors: Andrew Dauber, Ravi Savarirayan, Ricki Carroll, Moira Cheung, Valérie Cormier-Daire, Mohamad Maghnie, Noriyuki Namba, Oliver Semler, Sajda Ghani, Ian Sabir, Roberto Bassi Published: 2026 ABSTRACT AbstractBackgroundHypochondroplasia is a skeletal dysplasia characterized by disproportionate short stature that is caused by gain-of-function variants in the fibroblast growth factor receptor 3 gene (FGFR3), which negatively regulates endochondral bone growth. Current treatments are based on symptom management; there are no treatments targeting the signaling pathways that underlie hypochondroplasia. Vosoritide, a C-type natriuretic peptide analog that counteracts overactive FGFR3 signaling to stimulate endochondral bone growth, is approved for the treatment of achondroplasia in children. A phase 1/2 clinical trial demonstrated that vosoritide treatment for 1 year increased growth in children with hypochondroplasia and was well-tolerated.ObjectivesThe objectives of CANOPY HCH-3 are to evaluate the efficacy and safety of vosoritide for the treatment of hypochondroplasia in children.DesignCANOPY HCH-3 was a phase 3, randomized, double-blind, placebo-controlled, multicenter study.Methods and AnalysisChildren aged ≥3 to <18 years with confirmed hypochondroplasia who had ≥6 months of pre-treatment standing height from a prior observational study before randomization were enrolled. Participants were randomized to receive 52 weeks of daily treatment with vosoritide or placebo, followed by 2 weeks of safety follow-up. The primary endpoint is change from baseline in annualized growth velocity at week 52 versus placebo.EthicsCANOPY HCH-3 was conducted in accordance with the Council for International Organizations of Medical Sciences International Ethical Guidelines, the principles of the Declaration of Helsinki and of Good Clinical Practice, and applicable laws and regulations. Protocols were approved by relevant local health authorities, ethics committees, and institutions. Written informed consent from the participant, or parent or legal guardian, was obtained prior to any study-related procedures being performed.DiscussionCANOPY HCH-3 will provide further evidence for the efficacy and safety of vosoritide in children with hypochondroplasia.Keywords: hypochondroplasia, vosoritide, clinical trial, fibroblast growth factor receptor 3 Introduction Hypochondroplasia is a rare skeletal dysplasia characterized by disproportionate short stature that directly impacts the health and functioning of affected individuals.1,2 The true prevalence of hypochondroplasia is unknown due to the variability in its clinical presentation, probable underdiagnosis, and misdiagnosis but estimates range from 0.2 to 1.3 per 100,000 live births.3,4 Body disproportion is evident in early life and increases with age, with the height deficit accumulating over time. 1 In a study assessing growth data for children with a diagnosis of hypochondroplasia among a European background population, the height deficit was evident by 1 year of age, and by 4 years the average height was approximately 3 standard deviations (SD) below the average stature population. 5 By 16 years of age, the average height was 3.9 and 3.3 SD below the average stature population in female and male patients, respectively. 5 In addition to disproportionate short stature, affected individuals may present with relative macrocephaly, broad, short hands and feet with brachydactyly, limited elbow extension, mild joint laxity, and a thick, muscular build that may be described as stocky. 1 The associated complications of hypochondroplasia are multisystemic. In the youngest pediatric individuals (0–10 years), ear, nose and throat, respiratory, and neurocognitive comorbidities are most common; seizures may also be present.1,2,6 Quality of life is impaired, due to the impact of the condition on functional activities,7,8 and anxiety and depression may be linked to societal pressures about height and physical differences. 8 Hypochondroplasia is caused by gain-of-function variants in the fibroblast growth factor receptor 3 gene (FGFR3), causing overactivation of the receptor tyrosine kinase FGFR3 and its downstream signaling pathways, including the mitogen-activated protein kinase (MAPK) pathway.1,9 Under normal conditions, endogenous C-type natriuretic peptide (CNP) binds to its receptor, natriuretic peptide receptor-B (NPR-B), inhibiting MAPK signaling downstream of FGFR3, and triggering proliferation and differentiation of growth plate chondrocytes and synthesis of the extracellular matrix. 9 Constitutive FGFR3 activation causes an imbalance in these pathways, overriding the effects of endogenous CNP and resulting in the impaired endochondral bone growth that is characteristic of hypochondroplasia.1,9,10 The most frequently identified pathogenic variant in FGFR3 associated with hypochondroplasia is the N540K variant in the tyrosine kinase domain 1 of FGFR3, accounting for approximately 60%–70% of hypochondroplasia cases.11,12 Given that no single clinical or radiological feature is unique to hypochondroplasia, and that features overlap with other skeletal conditions, including achondroplasia, which is also caused by a gain-of-function variant in FGFR3, genetic detection of a hypochondroplasia-associated FGFR3 pathogenic variant is key to establishing an accurate diagnosis. 1 Treatment options for hypochondroplasia are limited. In Japan, recombinant human growth hormone (rhGH) is approved for the treatment of chondrodystrophies, including hypochondroplasia. 13 This approval was granted in the 1990s for 2 branded products (Humatrope® and Norditropin®) based on open-label studies conducted in Japan in children with chondrodystrophies treated at a dose of 0.35 mg/kg/week. In both studies, rhGH had an effect early in treatment, though gains in height attenuated as exposure increased (Humatrope [n = 18]: +0.60 standard deviation score [SDS] at year 1, +0.77 SDS at year 3; Norditropin: treatment naïve [n = 38], +0.52 SDS at year 1; 12–18 months of prior rhGH treatment [n = 9], +0.07 SDS at year 1). 14 Neither the US Food and Drug Administration (FDA) nor the European Medicines Agency (EMA) has approved rhGH for hypochondroplasia, despite its approval for several other pediatric growth conditions that similarly do not involve GH deficiency.15,16 This is likely due to studies demonstrating limited and inconsistent long-term efficacy, as summarized in a meta-analysis of 113 children with hypochondroplasia treated with rhGH (median [range] dosage, 0.25 [0.18–0.46] mg/kg/week), showing a mean height gain of +0.414, +0.530, and +0.609 SDS after 12, 24, and 36 months, respectively. 17 Other available treatment options for hypochondroplasia are based on the management of symptoms and include supportive care, limb-lengthening surgery, and surgery and medications for neurological manifestations.1,18 Limb-lengthening surgery can increase final adult height, but the procedure is complex with a long recovery time and a high risk of complications.1,19–21 There is no treatment available that targets the imbalance in the signaling pathways that underlie hypochondroplasia. Vosoritide is a CNP analog that counteracts overactive downstream FGFR3 signaling to stimulate endochondral bone growth. A phase 3 trial assessing vosoritide in children with achondroplasia demonstrated a sustained increase in growth velocity compared with placebo. 22 Vosoritide was approved for the treatment of achondroplasia in pediatric patients in 2021 in the US, and is also approved in the European Union, Japan, Brazil, and Australia.23–27 Due to the similarity in pathogenesis and disease manifestations between achondroplasia and hypochondroplasia, vosoritide is being investigated for use in hypochondroplasia. Data from a phase 2 study showed that when compared with the observation period, vosoritide increased growth in children with hypochondroplasia, with mean age- and sex-adjusted annualized growth velocity (AGV) increasing by 2.26 SD (P<0.0001; 95% CI, 1.48–3.05) and mean standing height SDS increasing by 0.36 SD (P<0.0001; 95% CI, 0.26–0.47) during the intervention period. 28 The safety profile was consistent with previously published reports in children with achondroplasia, with no treatment discontinuations due to adverse events (AEs). 28 These data suggest a comparable efficacy and safety profile for vosoritide in hypochondroplasia to that observed in the achondroplasia clinical development program, supporting initiation of a pivotal trial. Herein, we present the study design for CANOPY HCH-3, the phase 3 clinical trial of vosoritide in children with hypochondroplasia (111-303; NCT06455059). 29 Methods Study design and population CANOPY HCH-3 was a phase 3, randomized, double-blind, placebo-controlled, multicenter study comparing the efficacy and safety of vosoritide with placebo in children with hypochondroplasia. The trial took place from June 17, 2024 to April 23, 2026 at 23 hospitals in 9 countries (United States, Australia, Canada, France, Germany, Italy, Japan, Spain, and the United Kingdom). Before trial initiation, the protocol, informed consent form, and other relevant documents were reviewed and approved by the relevant institutional review boards or Independent Ethics Committees at each site. The study was conducted in accordance with the protocol as well as the Council for International Organizations of Medical Sciences International Ethical Guidelines, the principles of the Declaration of Helsinki and of Good Clinical Practice, and applicable laws and regulations. SPIRIT (Standard Protocol Items: Recommendations for Interventional Trials) guidelines were used to prepare this manuscript for publication.30,31 Participants Children aged 3 to <18 years of age who participated in the CANOPY HCH-OS observational study (111-902; NCT06212947) 32 and had at least 6 months of pre-treatment standing height prior to randomization were eligible to enroll. Of the eligible participants, a minimum of 10 participants were between the ages of 3 years and <6 years, 20 participants were between the ages of 6 years and <12 years, and 10 participants were between the ages of 12 years and <18 years. Additionally, participants had to have a confirmed genetic diagnosis of hypochondroplasia, as demonstrated by the presence of a pathogenic FGFR3 variant associated with hypochondroplasia (previously confirmed in the observational study CANOPY HCH-OS using whole genome sequencing with targeted analysis of FGFR3). If a variant of unknown significance was detected, the investigator established a diagnosis of hypochondroplasia based on the presence of a clinical phenotype consistent with hypochondroplasia, in consultation with a clinical geneticist and the sponsor’s medical monitor. Participants were required to be ambulatory, able to stand without assistance, and have a height Z-score of ≤−2.0 SDS in reference to the average stature population of the same age and sex, as calculated using the Centers for Disease Control and Prevention (CDC) growth charts (https://www.cdc.gov/growthcharts/cdc-data-files.htm). Participants were also required to have open growth plates as assessed by left hand antero-posterior X-rays. Participants were excluded if they had a short-stature condition other than hypochondroplasia, evidence of decreased growth velocity (AGV <1.5 cm/year) as assessed over a period of at least 6 months, comorbid conditions that could contribute to short stature, or current or prior use of medications that might affect growth. The full eligibility criteria are summarized in Table S1. Written informed consent was obtained from the participant or the participant’s parent or legal guardian by the investigator or their representative before any study-related procedures were performed, with a separate optional consent provided for the use of remaining blood samples in future research. Randomization and masking Participants were randomized in a 1:1 ratio to receive either vosoritide or placebo on day 1 after a 4-week screening period (Figure 1). Participants were assigned into 2 strata based on Tanner Stage (I or not evaluated due to age <5 years old, >I) with approximately 20% of participants having Tanner Stage >I. A separate randomization for Japanese participants recruited in Japan, without applying the Tanner stratification, was performed to ensure an even distribution of vosoritide and placebo. Approximately 20% of participants with a height Z-score less severe than −3.0 SDS (i.e., >−3.0 and ≤−2.0 SDS at screening) were enrolled in the study. Participants were randomized using an Interactive Web Response System (IWRS) developed by an independent third-party vendor, to ensure the study sponsor, site personnel, participants, caregivers, and outcome assessors were blinded to the treatment assignment. The IWRS was programmed with blind-breaking instructions in the event an investigator determined unblinding was necessary for participant safety. The sponsor could unblind the intervention assignment for any participant with a serious AE (SAE) in accordance with the sponsor’s standard operating procedure. CANOPY HCH-3 study design. aParticipants who completed the study, if eligible and consenting, had the option to enroll into the planned open-label extension study, CANOPY HCH-EXT. The 2-week safety follow-up visit could be waived for participants who entered the extension study within the 2-week period following last dose of study drug. ET, early termination; EXT, extension; HCH, hypochondroplasia; OS, observational study; SDS, standard deviation score. Study procedures The study consisted of up to 4 weeks of screening, 52 weeks of daily treatment with either vosoritide or placebo, and 2 weeks of safety follow-up. Participants who enrolled in CANOPY HCH-3 had the option to roll-over into CANOPY HCH-EXT, a long-term extension study (111-308; NCT07073014), 33 and receive treatment until final adult height is reached. Vosoritide dose was based on the participant’s weight and followed a weight-band dosing regimen as previously approved for achondroplasia participants weighing ≥10 kg in the US, EU, and other regions. This regimen, summarized in Table 1, is a refinement of the 15-μg/kg once-daily dose evaluated in the achondroplasia pivotal studies and ensures a more consistent exposure over the weight range of the hypochondroplasia study population. Table 1.Daily injection volumes to achieve the required weight-band dose.Body weight, kgDaily injection volume, mLConcentration: 0.8 mg/mL (0.56 mg/vial vosoritide + 0.7 mL water)Concentration: 2 mg/mL (1.2 mg/vial vosoritide + 0.6 mL water)10–110.30​12–160.35​17–210.40​22–320.50​33–43​0.2544–59​0.3060–89​0.35≥90​0.40 Daily injection volumes to achieve the required weight-band dose. To mitigate the risk of hypotension, participants were instructed to consume a light snack and approximately 240–300 mL of fluid within 1 hour before injection; families were advised to monitor for symptoms suggestive of hypotension, and physicians specifically assessed these symptoms at study visits. For on-site dosing, study treatment was administered by the investigator or designee under medical supervision, with the date, time, and dose volume recorded. Following administration of each dose, participants were observed for at least 2 hours after the injection on study visits day 1 and day 2, and were observed for 30 minutes for all other dose administration study visits. Trained caregivers were authorized to administer vosoritide or placebo at home. For home dosing, participants or caregivers were to record the date, time, injection site, dose volume, and any injection-site reactions in the study diary. Dose reduction was not permitted during the study, and any delay in treatment administration had to occur under the guidance of the Data Monitoring Committee (DMC). Permanent or temporary discontinuation of study treatment and recommencement/re-challenge in an individual was at the discretion of the investigator or study sponsor. Reasons for withdrawing a participant from study treatment included, but were not limited to, safety concerns, concerns related to study protocol adherence, pregnancy, or indication of reaching or approaching skeletal maturity (evidence of both growth plate fusion as assessed by radiographic imaging of distal femur and proximal tibial and an AGV <1.5 cm/yr as assessed over a period of at least 6 months). Compliance with study treatment was assessed at each visit by reconciliation of the used and unused vials. Participants were required to attend the study site for scheduled visits at screening, day 1, and day 2, and have visits scheduled every 3 months thereafter. All measures, with the exception of weight, were done in triplicate at approximately the same time for each visit (±2 hours) and assessors received standardized training by a specialized team on how to perform the measurements. Measurements were recorded to the nearest 0.1 cm or 0.1 kg. For all measurements except head circumference, if values differed by ≤0.5 cm, the mean was used, otherwise measurements were repeated until 3 consecutive values fell within these bounds; head circumference measurements were required to be within 0.3 cm of one another. In addition to vital signs and anthropometric measurements, full clinical assessments were performed at each visit, with the complete assessment schedule provided in Table 2. Table 2.Visit summary.ProcedureScreening D −28 to D −1D1D2D3D10 ± 1DW4 ± 7DW8 ± 7DW13 ± 7DW26 ± 7DW39 ± 7DW52 ± 7DSafety FU W54 ± 7DETInformed consent; demographics; medical history; height Z-score (derived); thyroid function testsX​​​​​​​​​​​​Randomization​X​​​​​​​​​​​Physical examinationXX​​​​​XXXX​XTanner StageX​​​​​​​X​X​XMenstrual history a XXX X X X X XXXX​XPregnancy testXX​​​​​XXXX​XVital signsXXX​​​​XXXX​XParental height b ​XAnthropometric measurements​X​​​​​XXXX​XQoLISSY; PedsQL; KABC-II; PGI-S; CaGI-S items​X​​​​​​​​X​XPGI-C; CaGI-C items​​​​​​​​​​X​XClinical hip assessmentX​​​​​​​X​X​XClinical labsXX​​​​​​X​X​XVitamin D, 25-hydroxyX​​​​​​​X​X​XAnti-vosoritide antibodies​X​​​​​​​​X​XUrine and serum bone metabolism biomarkers​X​​​​​​X​X​XVosoritide activity urine biomarkers​X​​​​​​​​X​​Transcriptomics assay c X​​​​​​X​​X​​PK​X​​​​​​X​X​​DXA d X​​​​​​​​​X​XLeft hand and wrist X-ray (PA view)X​​​​​​​​​X​XBilateral lower extremity and lumbar spine X-rays (AP and lateral views)​X​​​​​​​​X​​Concomitant medicationsXXX X X X X XXXX X XVosoritide/placebo administration​XX X X X X XXXX​​AE (including seizures and otitis media), SAEXXX X X X X XXXX X XProcedures and interventionsXXX X X X X XXXX X XVosoritide/placebo accountability​XX​​​​XXXX​XEntry and exit interviews c X​​​​​​​​​X​​Daily diary​XAssessments conducted by telephone are bolded. Relevant assessments were collected via dedicated diaries.aIn female participants.bIf not available from the CANOPY HCH-OS observational study, biological parental height assessment could occur any time during the study period.cOptional.dBMD and BMC of whole body (less head), lumbar spine.AE, adverse event; AP, antero-posterior; BMC, bone mineral content; BMD, bone mineral density; CaGI-S/C, Caregiver Global Impression of Severity/Change; cGMP, cyclic guanosine monophosphate; D, day; DXA, dual X-ray absorptiometry; ET; early termination; KABC-II: Kaufman Assessment Battery for Children – Second Edition; PGI-S/C, Patient Global Impression of Severity/Change; PK, pharmacokinetics; PGI-C and CaGI-C, Patient and Caregiver Global Impression of Change; PGI-S and CaGI-S, Patient and Caregiver Global Impression of Severity; PedsQL, Pediatric Quality of Life Inventory; QoLISSY, Quality of Life in Short Stature Youth; SAE, serious adverse event; W, week. Visit summary. Assessments conducted by telephone are bolded. Relevant assessments were collected via dedicated diaries. aIn female participants. bIf not available from the CANOPY HCH-OS observational study, biological parental height assessment could occur any time during the study period. cOptional. dBMD and BMC of whole body (less head), lumbar spine. AE, adverse event; AP, antero-posterior; BMC, bone mineral content; BMD, bone mineral density; CaGI-S/C, Caregiver Global Impression of Severity/Change; cGMP, cyclic guanosine monophosphate; D, day; DXA, dual X-ray absorptiometry; ET; early termination; KABC-II: Kaufman Assessment Battery for Children – Second Edition; PGI-S/C, Patient Global Impression of Severity/Change; PK, pharmacokinetics; PGI-C and CaGI-C, Patient and Caregiver Global Impression of Change; PGI-S and CaGI-S, Patient and Caregiver Global Impression of Severity; PedsQL, Pediatric Quality of Life Inventory; QoLISSY, Quality of Life in Short Stature Youth; SAE, serious adverse event; W, week. Data collection and management Sites entered study data into electronic case report forms (eCRFs) in the study electronic data capture system. Data quality control was performed by BioMarin Clinical Data Management or a designee. Study monitors performed ongoing source data verification to confirm that data entered into the eCRF by authorized site personnel were accurate, complete, and verifiable from source documents; that the safety and rights of participants were being protected; and that the study was being conducted in accordance with the approved protocol, the principles of Good Clinical Practice, and all applicable regulatory requirements. Participants were assigned a unique identifier by the sponsor, and any participant records or datasets that were transferred to the sponsor contained the identifier only. Participants’ privacy was protected in accordance with applicable local, national, and regional regulations and guidelines. Monitoring In addition to safety monitoring by the sponsor, an independent DMC acted as an advisory body and provided input on the blinded safety data collected in the study. Data were summarized by a third-party vendor with an independent statistician who communicated the analysis and results to the DMC members. This committee met every 6 months (or ad hoc as required). Outcomes The primary endpoint is change from baseline in AGV at week 52 versus placebo, where AGV is defined as and the interval length in days will be calculated as the number of days between the week 52 visit and the baseline visit. Baseline AGV will be established based on the standing height measurements taken as part of the CANOPY HCH-OS study in the 6 months prior to the CANOPY HCH-3 Day 1 date. The 6-month baseline assessment period could be longer depending on the timing of the visits for the 2 studies. Six key secondary endpoints will also be assessed as change from baseline at week 52 versus placebo in standing height, height Z-score (referenced to CDC average stature), arm span, upper to lower body segment ratio in participants aged <11 years at baseline, and the caregiver-administered total score and physical domain score of the Quality of Life in Short Stature Youth (QoLISSY) questionnaire (Table 3). Other secondary and exploratory endpoints include changes in biomarkers related to bone and collagen metabolism and vosoritide bioactivity and the evaluation of vosoritide pharmacokinetic (PK) parameters (summarized in Table S2). Prespecified subgroup analyses will be performed for the primary and 6 key efficacy endpoints (summarized in Table S3). Table 3.Primary and key secondary objectives and endpoints in the CANOPY HCH-3 trial.ObjectivesEndpoints Primary To evaluate the effect of vosoritide on AGV versus placebo• Change from baseline in AGV at week 52 versus placebo Key Secondary To evaluate the effect of vosoritide on standing height versus placebo• Change from baseline in standing height at week 52 versus placeboTo evaluate the effect of vosoritide on height Z-score versus placebo• Change from baseline in height Z-score at week 52 versus placeboTo evaluate the effect of vosoritide on arm span versus placebo• Change from baseline in arm span at week 52 versus placeboTo evaluate the effect of vosoritide on body proportions versus placebo• Change from baseline in upper to lower body segment ratio at week 52 versus placebo in participants aged <11 years at baselineTo evaluate changes in HRQoL versus placebo, as measured by QoLISSY• Change from baseline in the caregiver-administered total score of the QoLISSY at week 52 versus placebo• Change from baseline in the caregiver-administered physical domain score of the QoLISSY at week 52 versus placeboAGV, annualized growth velocity; HRQoL, health-related quality of life; QoLISSY, Quality of Life in Short Stature Youth. Primary and key secondary objectives and endpoints in the CANOPY HCH-3 trial. AGV, annualized growth velocity; HRQoL, health-related quality of life; QoLISSY, Quality of Life in Short Stature Youth. Safety will be evaluated by the incidence of AEs, SAEs, AEs of special interest (fracture, slipped capital femoral epiphysis, avascular necrosis or osteonecrosis, symptomatic hypotension), and clinically significant changes in vital signs, physical examination, imaging, and laboratory test results (urinalysis, chemistry, hematology) as judged by the investigator. Additionally, hip monitoring, biomarker, immunogenicity, and physical measurement data will be assessed. Assessments occurred at the time points shown in Table 2 or if unforeseen circumstances arose requiring an unscheduled visit. Sample size and power calculations A total of 80 participants were planned to be randomized into this study, with 40 participants per treatment group. This will provide the study with >90% power to detect a difference of 1.5 cm/year between the vosoritide group and the placebo group for the primary endpoint assuming the root mean square error (RMSE) in the analysis of covariance (ANCOVA) model is approximately 1.25. Sample size assumptions were based on the results from the primary analysis of the primary endpoint of CANOPY ACH-3 (111-301; NCT03197766), 34 change from baseline in AGV, which had a least squares mean difference of 1.57 cm/year and the model RMSE was 0.97. The power for the key secondary endpoint of change in standing height at week 52 is expected to be the same as that for AGV. For change in height Z-score at week 52, the study will have at least 88% power to detect a clinically meaningful difference of at least 0.25 SDS between the vosoritide group and the placebo group, assuming the RMSE in the ANCOVA model is approximately 0.35. The study will have 75% power if the treatment difference for arm span is half that observed for standing height (i.e., 0.75 cm), assuming the same root MSE as standing height. For upper to lower body segment ratio, the study will have approximately 70% power to detect a clinically meaningful difference of at least −0.05 between the vosoritide group and the placebo group, assuming the RMSE in the ANCOVA model is approximately 0.09. For the QoLISSY scores, power scenarios were based on observed SDs from the phase 3 clinical trial of vosoritide in patients with achondroplasia for the change from baseline at week 52. Group mean differences were determined by a factor of the standard error of measurement. Statistical plan The full analysis set (FAS; all randomized participants with a signed informed consent form) will be used to analyze endpoints related to efficacy objectives and for all endpoints not directly related to safety, PK, or immunogenicity. The primary and 6 key secondary efficacy endpoints will be assessed on the FAS and per protocol set (a subset of the FAS who are considered compliant with the protocol on all aspects that could affect the efficacy results). For the efficacy analyses, participants will be assessed as randomized according to the intent-to-treat principle on the FAS. The endpoints with their change from baseline will be summarized using descriptive statistics (mean, SD, median, minimum, and maximum) by randomized treatment group. The primary analysis to assess the change from baseline in AGV at week 52 will be based on an ANCOVA model, with fixed-effect terms including treatment group, sex, baseline age, baseline height Z-score, baseline Tanner Stage, and baseline AGV. The analysis of the 6 key secondary endpoints will follow the same process as for the primary endpoint (with baseline QoLISSY scores replacing the baseline growth parameters in the ANCOVA model for the analyses of the two QoLISSY key endpoints). Missing height data at week 52 will only be imputed for the primary and key secondary endpoint analyses on the FAS. Linear interpolation will be applied initially. In the event the week 52 height measurement remains missing, a retrieved dropout approach will be applied based on observed data from participants within the same treatment group who discontinue treatment but remain in study. Where there are insufficient numbers of retrieved dropouts to perform such imputation (i.e., fewer than 5 participants with reference data in the same treatment group who also discontinue treatment prematurely at a similar time point and have standing height assessments post treatment discontinuation), a placebo washout multiple imputation approach will be considered, in which missing data will be imputed based solely on placebo group data. If a participant died and their week 52 height measurement was missing, the last recorded height prior to death will be used as their final week 52 measurement. The safety set (all participants in the FAS who are exposed to study drug [active or placebo]) will be used to descriptively analyze endpoints and assessments related to safety. For the safety analyses, participants will be analyzed according to the study drug they received. All AEs will be coded using Medical Dictionary for Regulatory Activities (MedDRA) Version 28.1. Treatment-emergent AEs (TEAEs) will be summarized separately by treatment group. PK parameters generated over the course of the study will be summarized descriptively (mean, standard deviation, coefficient of variation percentage, min, median, and max), using the PK set (all participants in the FAS randomized to the vosoritide treatment group, who receive at least 1 dose of vosoritide and have at least 1 evaluable PK concentration). Immunogenicity will be summarized by study time point based on the immunogenicity set (i.e., all participants in the safety set who have at least 1 evaluable immunogenicity sample). Results will be summarized as incidence and titer. Role of the funding source This trial is sponsored by BioMarin Pharmaceutical Inc., Novato, CA, USA. The sponsor designed the study with input from the investigators, provided the study medication and matching placebo, and will analyze the data collected from the trial sites. Confidentiality agreements are in place between the sponsor and the investigators. Discussion Vosoritide was approved for the treatment of achondroplasia in pediatric patients in 2021 in the US, and it is also approved in the European Union, Japan, Brazil, and Australia.23–27 The safety of vosoritide in achondroplasia has been evaluated based on cumulative reported clinical and real-world data of ∼10,000 person-years, 14 and the overall clinical outcomes of vosoritide are supported by over a decade of clinical and real-world experience in achondroplasia.35–37 Data from the phase 1/2 trial of vosoritide in children with hypochondroplasia demonstrated that vosoritide treatment for 1 year increases growth in this population and that safety is consistent with previous published reports in children with achondroplasia,22,28 supporting the initiation of a phase 3 pivotal trial. The study design for this trial is similar to the design for the phase 3 study of vosoritide in children with achondroplasia, 22 and this protocol has been approved by the FDA and EMA, confirming regulatory alignment. The FGFR3 variants included in this study were based on documentation of a molecular diagnosis of hypochondroplasia obtained in CANOPY HCH-OS. During these studies, new variants for hypochondroplasia may be identified for further characterization. The identification of new hypochondroplasia-associated, pathogenic FGFR3 variants is an active area of research 38 that may help to explain the heterogeneity observed in hypochondroplasia clinical presentation and outcomes. The clinical heterogeneity of hypochondroplasia results in a spectrum of disease severity, with some individuals experiencing marked short stature and associated complications, while others have milder height reduction that resembles idiopathic or familial short stature. 1 Understanding whether these differences in patient characteristics influence responses to vosoritide, particularly its potential to improve patients’ height outcomes and quality of life, will be important to ensure that patients taking vosoritide are likely to achieve the desired outcomes. Furthermore, identifying genetic and transcriptional variants that modify hypochondroplasia presentation, or that may influence CNP signaling or the efficacy and safety profile of vosoritide — as will be explored using whole genome sequence data and transcriptome profiles obtained from blood samples collected during the study — may provide insight into the molecular mechanisms underlying the disease and drug action. Reports of neurological complications such as learning disabilities, intellectual disabilities, developmental delays, and seizures are more common in individuals with hypochondroplasia than in those with achondroplasia or the general public.1,2,6,39 Structural abnormalities have been found in the temporal lobes of patients with hypochondroplasia and a clinical indication for brain magnetic resonance imaging. 6 FGFR3 is expressed in the brain during development and is involved in controlling cortex formation by regulating cortical progenitor cell proliferation and apoptosis. 40 This function, separate from regulation of bone growth, likely plays a role in these neurological complications, though it is unclear what aspect of the FGFR3 variants underlying hypochondroplasia makes these neurological phenotypes more prevalent relative to achondroplasia. Given that vosoritide does not substantially cross the blood-brain barrier, 41 and the likely developmental origin of the neurological complications, vosoritide treatment is not expected to have an effect on this domain of the condition. Limitations With a treatment period limited to 1 year, this study does not allow the effect of vosoritide on final adult height to be directly evaluated. Several of the study objectives related to evaluating quality of life may also require longer monitoring for treatment differences to accumulate, as was the case for children with achondroplasia, in whom improvements in physical and social domains of health-related quality of life did not become evident until after 3 years of vosoritide treatment. 42 Data from longer-term studies — such as CANOPY HCH-EXT, which will evaluate the efficacy and safety of vosoritide until final adult height is reached 33 — will help to address questions that require extended treatment to be answered. A further limitation of the study relates to the height Z-score inclusion criterion, which may reduce the already narrow therapeutic window for intervention before puberty. This criterion restricted study enrollment to children with a height Z-score of ≤−2.0 SDS in reference to the average stature population (by sex and age). The proposed minimum height Z-score threshold corresponds with the definition of short stature (height Z-score <−2.0). 43 However, considering the height deficit in hypochondroplasia typically widens during puberty due to the condition’s attenuation of the pubertal growth spurt,5,28 use of a height Z-score ≤−2.0 SDS in early childhood may exclude individuals who later develop a compromised adult height and who might have benefited from earlier intervention, when treatment is thought to be most effective. This criterion was not included in the phase 3 study of vosoritide for achondroplasia, given that achondroplasia typically causes height deficits well below −2.0 SDS, 44 but it was used in this study to ensure that a growth-promoting agent was not administered to children whose height deficit is not considered pathological. Considering the wide age range eligible for inclusion (3 up to <18 years), some participants could have approached or reached growth plate closure during the study, which would significantly affect growth outcomes. Although possible, this concern was mitigated by excluding patients with evidence of decreased growth velocity (AGV <1.5 cm/year as assessed over a period of at least 6 months) prior to enrollment. If any patients did reach skeletal maturity during the treatment period, they would be identified as part of the imaging performed at the end of the study to assess bone age (left hand and wrist X-ray) and growth plates (bilateral X-rays of lower extremity). Prespecified imaging assessments were restricted to the beginning and end of the study to reduce unnecessary radiation exposure. However, if AGV slowed to <1.5 cm/year, additional imaging may have been warranted to assess growth plate status, as is recommended when monitoring vosoritide treatment in children with achondroplasia. 18 If closed, study treatment would have been discontinued for the participant. Across this wide age range, the greatest proportion of patients were in the 6 to 12 years age span compared with younger children and adolescents. Randomization and stratification by Tanner Stage should help to ensure that the influence of age and pubertal status on growth potential is balanced across the treatment and placebo groups. Additionally, the primary and key secondary analyses will use an ANCOVA model that includes fixed effects terms for baseline age and Tanner Stage to further help adjust and control for heterogeneity in age and pubertal status among participants. Planned subgroup analyses will also aid in evaluating whether the effect of vosoritide treatment varies across age groups and by pubertal status. In children with achondroplasia, subgroup analyses for change from baseline in AGV for age and Tanner Stage categories all favored vosoritide and all had overlapping 95% CIs. 22 Conclusions Efficacy data to date for vosoritide in hypochondroplasia is limited to preliminary evidence. This pivotal trial aims to provide the first confirmatory evidence for the efficacy and safety of a CNP analog in children with hypochondroplasia. Infigratinib, an orally bioavailable selective tyrosine kinase inhibitor of FGFR1-3, is being investigated for the treatment of hypochondroplasia, with primary completion of the phase 2/3 trial not expected until 2027. 45 The results of CANOPY HCH-3, if positive, may therefore help to establish vosoritide as the first approved targeted therapeutic option for hypochondroplasia. Supplemental material Supplemental material - A phase 3, randomized, double-blind, placebo-controlled, multicenter study to evaluate the efficacy and safety of vosoritide in children with hypochondroplasia: CANOPY HCH-3 study design Supplemental material for A phase 3, randomized, double-blind, placebo-controlled, multicenter study to evaluate the efficacy and safety of vosoritide in children with hypochondroplasia: CANOPY HCH-3 study design by Andrew Dauber, Ravi Savarirayan, Ricki Carroll, Moira Cheung, Valérie Cormier-Daire, Mohamad Maghnie, Noriyuki Namba, Oliver Semler, Sajda Ghani, Ian Sabir, and Roberto Bassi in Therapeutic Advances in Endocrinology and Metabolism. Acknowledgements We thank the patients and their families for their participation in these studies; the collaborating institutions and study personnel at the participating study sites; the members of the study data monitoring committee; and BioMarin clinical operations, statisticians, and data science teams. Medical writing and editorial support, under the guidance of the authors, were provided by Katherine Price, PhD, an employee from the Publications and Medical Affairs Division of Omnicom Health Medical Communications, and were funded by BioMarin Pharmaceutical Inc., San Rafael, CA, USA, in accordance with Good Publication Practice, GPP 2022 (Ann Intern Med 2022; 175:1298-1304). Author contributions: Andrew Dauber: Conceptualization; Investigation; Writing – review & editing. Ravi Savarirayan: Conceptualization; Investigation; Methodology; Supervision; Writing – review & editing. Ricki Carroll: Conceptualization; Investigation; Writing – review & editing. Moira Cheung: Investigation; Writing – review & editing. Valérie Cormier-Daire: Conceptualization; Investigation; Methodology; Supervision; Writing – review & editing. Mohamad Maghnie: Conceptualization; Investigation; Supervision; Writing – review & editing. Noriyuki Namba: Conceptualization; Investigation; Writing – review & editing. Oliver Semler: Conceptualization; Investigation; Supervision; Writing – review & editing. Sajda Ghani: Methodology; Software; Writing – review & editing. Ian Sabir: Conceptualization; Methodology; Writing – review & editing. Roberto Bassi: Conceptualization; Investigation; Methodology; Project administration; Supervision; Writing – review & editing. Funding: The authors disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: This trial was funded by BioMarin Pharmaceutical Inc. Andrew Dauber has received grant funding from BioMarin and has served as a consultant for BioMarin with compensation paid to his employer. Ravi Savarirayan has received consulting fees and honoraria from BioMarin, Ascendis Pharma, QED, and Tyra. Ricki Carroll has served as a consultant/advisor for BioMarin, Ascendis, QED/BridgeBio, Actio, and Guidepoint; is a current or prior investigator on trials for BioMarin, Ascendis, Tyra, Ultragenyx. Moira Cheung received consultancy honoraria and speaking fees from BioMarin, BridgeBio, Kyowa Kirin, and Tyra BioSciences; is a current or prior investigator on trials from BioMarin and Tyra BioSciences and is on the DMC for Ascendis Pharma. Valérie Cormier-Daire has received speaking fees from BioMarin; is a current or prior investigator on trials from BioMarin, QED/BridgeBio, Ultragenyx. Mohamad Maghnie has received grant support from Pfizer, Novo Nordisk, Merck Serono, Ascendis and Rhythm Pharmaceuticals and consultancy; has received honoraria and speaking fees from Pfizer, Merck Serono, Novo Nordisk, Sandoz, BioMarin, and Rhythm Pharmaceuticals. Noriyuki Namba has received consultancy/advisory board honoraria from BioMarin, Kyowa Kirin, Ascendis, Teijin and speaking fees from BioMarin, Kyowa Kirin, Teijin, and Novo Nordisk; is a current or prior investigator on trials for BioMarin, Kyowa Kirin, Ascendis, and Teijin. Oliver Semler has received honoraria and compensation for advisory activities from BioMarin, Alexion, Ascendis, Kyowa Kirin, Merck, Mereo, Ultragenyx. Sajda Ghani is an employee of BioMarin Pharmaceutical Inc. and owns shares/stocks in the company. Ian Sabir is an employee of BioMarin Pharmaceutical Inc. and owns shares/stocks in the company. Roberto Bassi is an employee of BioMarin Pharmaceutical Inc. and owns shares/stocks in the company. Registration: Clinicaltrials.gov: NCT06455059. Supplemental material: Supplemental material for this article is available online. ORCID iDs Andrew Dauber https://orcid.org/0000-0003-4890-0262 Valérie Cormier-Daire https://orcid.org/0000-0002-2839-9856 Ethical considerations Before trial initiation, the protocol, informed consent form, and other relevant documents were reviewed and approved by the relevant institutional review boards or Independent Ethics Committees at each study site: Tottori University Hospital Institutional Review Board (IRB; approval #25Oct2024), Institute of Science Tokyo Hospital IRB (approval #23Dec2024), Osaka University Hospital IRB (approval #9Oct2024), Tokushima University Hospital IRB (approval #19Dec2024), Comité de protection des personnes Ile de France V Hôpital SAINT ANTOINE (approval #N/A, EUCT #2024-513129-22-00), Ethikkommission an der Technischen Universität München (approval #N/A, EUCT #2024-513129-22-00), Comitato Etico per le Sperimentazioni Cliniche in Ambito Pediatrico (approval #N/A, EUCT #2024-513129-22-00), Fundació Sant Joan de Déu Santa Rosa (approval #N/A, EUCT #2024-513129-22-00), Brighton & Sussex Research Ethics Committee Health Research Authority (approval #N/A), Advarra IRB (FDA/OHRP IRB Registration #: IRB00000971), Ann & Robert H. Lurie Children’s Hospital of Chicago IRB (FWA: 00001011; IRB Registration # 00000624 and 00009723), MCW IRB (FWA00000820), Nemours Children’s Health IRB 1 (FWA: 00000293), University of Alberta Health Research Ethics Board (FWA00014282), The Hospital for Sick Children Research Ethics Board (IRB #00000983, 00007529, and 00013726; FWA00000281), Comite d’ethique de la recherche du CHU Sainte-Justine (approval #2025-7630). The study was conducted in accordance with the protocol as well as the Council for International Organizations of Medical Sciences International Ethical Guidelines, the principles of the Declaration of Helsinki and of Good Clinical Practice, and applicable laws and regulations. Consent to participate Written informed consent from the participant, or parent or legal guardian, was obtained prior to any study-related procedures being performed. Data Availability Statement The sponsor recognizes the importance of communicating medical study data and therefore encourages the publication of data from this study in reputable scientific journals and at seminars or conferences. The posting of study information and study results will comply with applicable national regulatory requirements and the sponsor’s data sharing policy available at https://www.biomarin.com/wp-content/uploads/2024/03/BioMarin-Data-Sharing-Request-Policy.pdf. References Associated Data Supplementary Materials Supplemental material - A phase 3, randomized, double-blind, placebo-controlled, multicenter study to evaluate the efficacy and safety of vosoritide in children with hypochondroplasia: CANOPY HCH-3 study design Supplemental material for A phase 3, randomized, double-blind, placebo-controlled, multicenter study to evaluate the efficacy and safety of vosoritide in children with hypochondroplasia: CANOPY HCH-3 study design by Andrew Dauber, Ravi Savarirayan, Ricki Carroll, Moira Cheung, Valérie Cormier-Daire, Mohamad Maghnie, Noriyuki Namba, Oliver Semler, Sajda Ghani, Ian Sabir, and Roberto Bassi in Therapeutic Advances in Endocrinology and Metabolism. Data Availability Statement The sponsor recognizes the importance of communicating medical study data and therefore encourages the publication of data from this study in reputable scientific journals and at seminars or conferences. The posting of study information and study results will comply with applicable national regulatory requirements and the sponsor’s data sharing policy available at https://www.biomarin.com/wp-content/uploads/2024/03/BioMarin-Data-Sharing-Request-Policy.pdf.